Irinotecan-hyaluronic acid complex

Drug Profile

Irinotecan-hyaluronic acid complex

Alternative Names: HA-irinotecan; Hyaluronan irinotecan complex; Hyaluronic acid irinotecan complex; HyCAMP; Irinotecan hyaluronan complex

Latest Information Update: 01 May 2015

Price : $50

At a glance

  • Originator Monash University
  • Developer Alchemia
  • Class Alkaloids; Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Suspended Colorectal cancer

Most Recent Events

  • 01 May 2015 Alchemia suspends a phase II trial in Colorectal cancer in Australia (NCT02216487)
  • 01 May 2015 Irinotecan-hyaluronic acid complex is still in phase II development for Small cell lung cancer in Australia
  • 29 Jan 2015 Suspended - Phase-III for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, Ukraine, Serbia, Russia, Bulgaria, United Kingdom, Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top